IP Library Granted Patent US 11,634,748
Granted Patent B2
US 11,634,748 · App. 16/275,237 · Granted Apr 25, 2023

Methods for the epigenetic analysis of DNA, particularly cell-free DNA

Inventors: Patrick A. Arensdorf (Palo Alto, CA); Damek Spacek (Palo Alto, CA)
Assignee: CLEARNOTE HEALTH, INC.
C12Q1/6806C07H19/06C07H21/04C07J1/00C12Q1/6827C12Q1/6869C12Q2523/10C12Q2523/115C12Q2537/164
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,634,748
App. No.
16/275,237
Granted
Apr 25, 2023
Kind
B2
Abstract

Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane selected to successively bring about reduction, deamination, and decarboxylation of oxidized 5-methylcytosine residues such as 5-carboxymethylcytosine and 5-formylcytosine, resulting in DHU residues in place thereof. Following amplification, the treated cell-free DNA is sequenced, with the DHU residues read as thymine residues. Reaction mixtures, kits and additional methods are also provided, as are related methods for the epigenetic analysis of DNA, including cell-free DNA.

Claims (13)

1. A method for identifying 5hmC locations in adapter-ligated target DNA in a cell-free DNA sample, the method comprising:

(a) oxidizing 5hmC in the target DNA with an oxidizing reagent to yield DNA containing oxidized 5hmC without affecting 5mC, wherein the oxidized 5hmC is selected from 5caC, 5fC, and combinations thereof;

(b) reacting the DNA containing oxidized 5hmC with pyridine borane to reduce, deaminate, and either decarboxylate or deformylate the oxidized 5hmC, thereby providing modified DNA containing DHU in place of the oxidized 5hmC;

(c) amplifying and sequencing the modified DNA to provide 5hmC-indicative sequence reads; and

(d) comparing the 5hmC-indicative sequence reads to standard sequence reads obtained for the target molecule, wherein a change from C in the standard sequence reads to a T in the 5hmC-indicative sequence reads indicates a 5hmC location.

2. The method of claim 1 , wherein steps (a) through (c) are carried out without isolation of any intermediates.

3. The method of claim 1 , wherein steps (a) through (c) are carried out in the absence of bisulfite.

4. The method of claim 1 , wherein step (a) is carried out using a chemical oxidizing reagent.

5. The method of claim 4 , wherein the chemical oxidizing reagent is a perruthenate salt.

6. The method of claim 1 , wherein the adapter-ligated DNA comprises adapters containing a sample identifier sequence and at least one additional molecular barcode selected from a fragment identifier sequence and a strand identifier sequence.

7. The method of claim 6 , wherein the adapter-ligated DNA comprises both a fragment identifier sequence and a strand identifier sequence.

8. The method of claim 1 , wherein the cell-free DNA comprises double-stranded DNA.

9. The method of claim 1 , wherein the cell-free DNA comprises single-stranded DNA.

Assignments (2)
CHANGE OF NAME Recorded Feb 24, 2023
From: BLUESTAR GENOMICS, INC.
To: CLEARNOTE HEALTH, INC.
Reel/Frame 062857/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: ARENSDORF, PATRICK A.; SPACEK, DAMEK
To: BLUESTAR GENOMICS, INC.
Reel/Frame 054610/0691 →
Continuity (2)
Provisional Application 62630798 · Feb 14, 2018
Related Publication 20200024643A1 · Jan 23, 2020
Cited By (3)
US 12,351,859 US 12,540,319 US 12,630,866